Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of common stock of Esperion Therapeutics, Inc. in a Schedule 13G filing. They report aggregate beneficial ownership of 17,222,156.04 shares of Esperion common stock, representing 6.7% of the class. The reporting persons disclose shared voting power over 17,216,493.04 shares and shared dispositive power over 17,216,538.04 shares, with no sole voting or dispositive power. Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser, is a subsidiary of The Goldman Sachs Group, Inc., and the filing reflects securities held by specified Goldman Sachs reporting units, which disclaim beneficial ownership in certain client and managed entities.
Vanguard Capital Management reports beneficial ownership of common stock of Esperion Therapeutics Inc. Vanguard and certain affiliates hold 13,105,104 shares, representing 5.08% of Esperion’s common stock. Vanguard has sole voting power over 1,677,667 shares and sole dispositive power over 13,105,104 shares, with no shared voting or dispositive power.
The position is held across Vanguard investment companies and other managed accounts for which Vanguard and specified affiliates exercise dispositive and/or voting authority. Dividends and sale proceeds are for the benefit of these funds and clients, and no other single person has an interest in more than 5% of the class.
Wasatch Advisors reports beneficial ownership of 1,930,185 Esperion Therapeutics shares, representing 0.7% of the company’s stock class. The position carries sole voting power and sole dispositive power over all of these shares, with no shared voting or dispositive authority.
The disclosure characterizes this stake as “Ownership of 5 percent or less of a class,” indicating that Wasatch Advisors holds a relatively small fraction of Esperion’s outstanding stock.